NO944912L - Fremgangsmåte for å öke makrofagfunksjonen - Google Patents

Fremgangsmåte for å öke makrofagfunksjonen

Info

Publication number
NO944912L
NO944912L NO944912A NO944912A NO944912L NO 944912 L NO944912 L NO 944912L NO 944912 A NO944912 A NO 944912A NO 944912 A NO944912 A NO 944912A NO 944912 L NO944912 L NO 944912L
Authority
NO
Norway
Prior art keywords
macrophage function
steps
increase macrophage
increase
hexamethyleneamino
Prior art date
Application number
NO944912A
Other languages
English (en)
Other versions
NO944912D0 (no
Inventor
Steven Harold Zuckerman
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO944912D0 publication Critical patent/NO944912D0/no
Publication of NO944912L publication Critical patent/NO944912L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det er beskrevet en fremgangsmåte for å øke makrofag- funksjonen Innbefattende administrering til en menneske som har behov for dette av en effektiv mengde av en forbindelse som har formelen OCH:CHi¿R2 OR1 (I) hvor R1 og R3 uavhengig av hverandre er hydrogen, - O O ^, alkyl ) , eller .-C-Ar, hvor Ar er eventuelt substituert fenyl; R5* er valgt fra gruppen bestående av pyrrolldln, heksametylenamlno og plperidino; eller et farmasøytisk akseptabelt salt eller solvat derav.
NO944912A 1993-12-21 1994-12-19 Fremgangsmåte for å öke makrofagfunksjonen NO944912L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/170,605 US5672610A (en) 1993-12-21 1993-12-21 Methods of increasing macrophage function

Publications (2)

Publication Number Publication Date
NO944912D0 NO944912D0 (no) 1994-12-19
NO944912L true NO944912L (no) 1995-06-22

Family

ID=22620563

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944912A NO944912L (no) 1993-12-21 1994-12-19 Fremgangsmåte for å öke makrofagfunksjonen

Country Status (16)

Country Link
US (1) US5672610A (no)
EP (1) EP0659425A1 (no)
JP (1) JPH07215861A (no)
KR (1) KR950016721A (no)
CN (1) CN1049818C (no)
AU (1) AU693127B2 (no)
CA (1) CA2138492A1 (no)
CZ (1) CZ320794A3 (no)
HU (1) HUT71475A (no)
IL (1) IL112032A (no)
NO (1) NO944912L (no)
NZ (1) NZ270165A (no)
PH (1) PH31267A (no)
RU (1) RU94044455A (no)
TW (1) TW321599B (no)
ZA (1) ZA9410081B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
DK1175433T3 (da) 1999-05-04 2005-09-19 Strakan Int Ltd Androgenglycosider og androgen aktivitet deraf

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
JPS62201819A (ja) * 1985-11-13 1987-09-05 Res Dev Corp Of Japan 免疫不全症処置剤
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体

Also Published As

Publication number Publication date
AU693127B2 (en) 1998-06-25
HUT71475A (en) 1995-11-28
US5672610A (en) 1997-09-30
KR950016721A (ko) 1995-07-20
HU9403659D0 (en) 1995-02-28
PH31267A (en) 1998-06-18
CZ320794A3 (en) 1995-09-13
NO944912D0 (no) 1994-12-19
JPH07215861A (ja) 1995-08-15
IL112032A0 (en) 1995-03-15
RU94044455A (ru) 1996-10-10
CN1049818C (zh) 2000-03-01
CA2138492A1 (en) 1995-06-22
AU8155194A (en) 1995-06-29
EP0659425A1 (en) 1995-06-28
ZA9410081B (en) 1996-06-19
NZ270165A (en) 1997-08-22
IL112032A (en) 1999-03-12
TW321599B (no) 1997-12-01
CN1108092A (zh) 1995-09-13

Similar Documents

Publication Publication Date Title
NO944911L (no) Ikke-peptid-takykininreseptorantagonister
NO944928L (no) Fremgangsmåter for inhibering av Alzheimers sykdom
NO944914L (no) Fremgangsmåte for å inhibere autoimmunsykdommer
MY132056A (en) Methods of inhibiting physiological conditions associated with an excess of neuropeptide y.
NO944919L (no) Fremgangsmåte for å inhibere atrofi av huden eller vagina
NO944927L (no) Fremgangsmåte for inhibering av pulmonar hypertensiv sykdom
TW352382B (en) Substituted sulfonimidamides, processes for their preparation, their use as a medicament of diagnostic, and medicament comprising them
NO944926L (no) Fremgangsmåter for å inhibere myeloperoksidaseaktivitet
NO944934L (no) Hemming av vasomotoriske symptomer og tilhörende psykologiske forstyrrelser i forbindelse med post-menopausalt syndrom
DK0651999T3 (da) Fremgangsmåder til inhibering af livmoderfibrose
MX9701325A (es) Metodos para inhibir la mucositis ulcerativa.
NO944933L (no) Fremgangsmåte for å inhibere sykdomstilstander i brystet
MX9701360A (es) Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.
NO944930L (no) Hemming av dysfunksjonell uterin blödning
DE68903437D1 (de) Piperidin-derivate.
NO944924L (no) Fremgangsmåter for inhibering av Turner's syndrom
DK0659427T3 (da) 2-Phenyl-3-azoylbenzothiophener til forøgelse af thrombomodulinekspression
NO944931L (no) Anvendelse av 2-fenyl-3-aroylbenzotiofener for inhibering av tidlig seksuell modenhet
NO975580L (no) Fremgangsmåte for å inhibere melanom
NO973367L (no) Fremgangsmåte for å inhibere miljömessige östrogen
NO944912L (no) Fremgangsmåte for å öke makrofagfunksjonen
NO981578L (no) FremgangsmÕte for hemming av plasminogenaktivatorhemmer I
NO944577L (no) Hemming av effekten av amyloidogene proteiner
NZ236186A (en) Pyrrolidine and piperidine derivatives and pharmaceutical compositions
NO973609L (no) Fremgangsmåte for å inhibere effektene av IL-6